Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar-Nana F, Ponce S, Dal Maso A, Spotti M, Mielgo-Rubio X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Planchard D, Mezquita L. Riudavets M, et al. Among authors: mezquita l. Eur J Cancer. 2022 May;167:142-148. doi: 10.1016/j.ejca.2022.02.014. Epub 2022 Mar 17. Eur J Cancer. 2022. PMID: 35307254
Vaccine Therapy in Non-Small Cell Lung Cancer.
García-Pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. García-Pardo M, et al. Among authors: mezquita l. Vaccines (Basel). 2022 May 9;10(5):740. doi: 10.3390/vaccines10050740. Vaccines (Basel). 2022. PMID: 35632496 Free PMC article. Review.
Targeting molecular alterations in non-small-cell lung cancer: what's next?
López-Castro R, García-Peña T, Mielgo-Rubio X, Riudavets M, Teixidó C, Vilariño N, Couñago F, Mezquita L. López-Castro R, et al. Among authors: mezquita l. Per Med. 2022 Jul;19(4):341-359. doi: 10.2217/pme-2021-0059. Epub 2022 Jun 24. Per Med. 2022. PMID: 35748237 Review.
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E, Benitez-Montanez J, Tagliamento M, Parisi F, Gorria T, Garcia-Campelo R, Dempsey N, Pinato DJ, Reyes R, Albarrán-Artahona V, Dall'Olio F, Soldato D, Hendriks L, Nana FA, Tonneau M, Lopez-Castro R, Nadal E, Kazandjian S, Muanza T, Blanc-Durand F, Fabre E, Castro N, Arasanz H, Rochand A, Besse B, Routy B, Mezquita L. Auclin E, et al. Among authors: mezquita l. Lung Cancer. 2023 Apr;178:116-122. doi: 10.1016/j.lungcan.2023.02.002. Epub 2023 Feb 4. Lung Cancer. 2023. PMID: 36812760
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar Nana F, Ponce S, Albarrán-Artahona V, Dal Maso A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, Planchard D. Riudavets M, et al. Among authors: mezquita l. Clin Lung Cancer. 2024 May;25(3):233-243.e8. doi: 10.1016/j.cllc.2023.11.007. Epub 2023 Nov 22. Clin Lung Cancer. 2024. PMID: 38105153
162 results